Guerbet SA's latest marketcap:
As of 08/13/2025, Guerbet SA's market capitalization has reached $325.32 M. According to our data, Guerbet SA is the 17474th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 325.32 M |
| Revenue (ttm) | 996.32 M |
| Net Income (ttm) | 18.83 M |
| Shares Out | 12.6 M |
| EPS (ttm) | 1.49 |
| Forward PE | 10.31 |
| Ex-Dividend Date | 07/01/2024 |
| Earnings Date | 09/24/2025 |
Guerbet SA's yearly market capitalization.
| Date | Market Cap(€) | Market Cap(USD) | Change (%) | Global Rank |
|---|---|---|---|---|
| 08/13/2025 | €277.91 M | $325.32 M | -17.76% | 17474 |
| 12/31/2024 | €337.92 M | $349.82 M | 37.29% | 15383 |
| 12/29/2023 | €246.14 M | $271.67 M | 14.95% | 17021 |
| 12/30/2022 | €214.13 M | $229.17 M | -54.42% | 17221 |
| 12/31/2021 | €469.83 M | $534 M | 13.67% | 12919 |
| 12/31/2020 | €413.32 M | $504.82 M | -20.32% | 11543 |
| 12/31/2019 | €518.75 M | $581.67 M | -21.07% | 9293 |
| 12/31/2018 | €657.27 M | $753.63 M | -33.74% | 7187 |
| 12/29/2017 | €992 M | $1.19 B | 12.21% | 6397 |
| 12/30/2016 | €884.03 M | $929.65 M | 11.94% | 6809 |
Company Profile
About Guerbet SA
Guerbet SA specializes in the development and commercialization of contrast media products, medical devices, and digital healthcare solutions. Founded in 1926 and headquartered in Villepinte, France, the company serves diagnostic and interventional radiology markets worldwide.
Core Offerings
- Contrast Media: Non-ionic monomeric agents (Optiray, Xenetix), meglumine ioxitalamate (Telebrix Gastro), iothalamate meglumine (Conray), and gadoteric acid-based solutions (Dotarem, Artirem) for MRI and CT imaging.
- Diagnostic Solutions: Micropaque/Microtrast for imaging, prefilled syringes, injectors, and consumables for MRI, CT, and Cath Lab procedures.
- Digital Healthcare: AI-driven platforms like Contrast&Care (injection management), Dose&Care (X-ray dose tracking), and icobrain (neurological quantification).
- Interventional Radiology: Products such as Lipiodol, Vectorio (chemoembolization system), Patent Blue V dye, Axessio guidewires, and SeQure/DraKon microcatheters.
- Urology & Gastroenterology: Hydra Vision digital imaging system and specialized accessories for diagnostic and treatment procedures.
Guerbet SA combines innovation with precision to enhance medical imaging and patient care across global healthcare systems.
Frequently Asked Questions
-
What is Guerbet SA's (EPA-GBT) current market cap?As of 08/13/2025, Guerbet SA (including the parent company, if applicable) has an estimated market capitalization of $325.32 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Guerbet SA (EPA-GBT) rank globally by market cap?Guerbet SA global market capitalization ranking is approximately 17474 as of 08/13/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.